Vera Therapeutics

Vera is developing atacicept, a novel biologic drug for the treatment of IgA nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease and early death. Atacicept is a recombinant fusion protein that contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as IgA Nephropathy (IgAN).